Cantor Fitzgerald Reaffirms “Overweight” Rating for Sanara MedTech (NASDAQ:SMTI)

Cantor Fitzgerald reissued their overweight rating on shares of Sanara MedTech (NASDAQ:SMTIFree Report) in a report issued on Tuesday morning, Benzinga reports. Cantor Fitzgerald currently has a $49.00 price objective on the stock.

Separately, TheStreet cut shares of Sanara MedTech from a c- rating to a d+ rating in a research note on Friday, October 20th.

Read Our Latest Stock Report on Sanara MedTech

Sanara MedTech Stock Up 4.1 %

NASDAQ:SMTI opened at $40.20 on Tuesday. Sanara MedTech has a fifty-two week low of $26.06 and a fifty-two week high of $50.18. The stock has a market capitalization of $343.31 million, a P/E ratio of -40.20 and a beta of 1.55. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.09 and a current ratio of 1.46. The company’s 50-day simple moving average is $37.40 and its 200-day simple moving average is $35.38.

Sanara MedTech (NASDAQ:SMTIGet Free Report) last released its quarterly earnings results on Monday, November 13th. The company reported ($0.13) earnings per share for the quarter. Sanara MedTech had a negative net margin of 13.05% and a negative return on equity of 20.51%. The firm had revenue of $16.03 million during the quarter. On average, equities analysts anticipate that Sanara MedTech will post -0.7 earnings per share for the current fiscal year.

Institutional Trading of Sanara MedTech

A number of institutional investors have recently bought and sold shares of the stock. Tower Research Capital LLC TRC raised its position in Sanara MedTech by 363.4% during the 3rd quarter. Tower Research Capital LLC TRC now owns 797 shares of the company’s stock worth $25,000 after buying an additional 625 shares during the last quarter. UBS Group AG raised its position in Sanara MedTech by 138.8% during the 1st quarter. UBS Group AG now owns 609 shares of the company’s stock worth $25,000 after buying an additional 354 shares during the last quarter. Barclays PLC purchased a new position in Sanara MedTech during the 2nd quarter worth approximately $30,000. Strs Ohio purchased a new position in Sanara MedTech during the 2nd quarter worth approximately $32,000. Finally, Gladius Capital Management LP purchased a new position in Sanara MedTech during the 4th quarter worth approximately $45,000. 7.83% of the stock is currently owned by institutional investors and hedge funds.

About Sanara MedTech

(Get Free Report)

Sanara MedTech Inc develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. It also offers CellerateRX Surgical Activated Collagen powder and gel that are used in a range of surgical specialties to help promote patient healing; Biako¯s Antimicrobial Skin and Wound Cleanser, a patented product that disrupts extracellular polymeric substances to eradicate mature biofilm microbes; Biako¯s Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing helps against planktonic microbes, as well as immature and mature biofilms; and Biako¯s Antimicrobial Skin and Wound Irrigation Solution.

Featured Stories

Receive News & Ratings for Sanara MedTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanara MedTech and related companies with MarketBeat.com's FREE daily email newsletter.